Dicerna Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Dicerna Pharmaceuticals, Inc. (“Dicerna” or the “Company”) (NASDAQ: DRNA) to Novo Nordisk (“Novo). Under the terms of the merger Novo will initiate a tender offer to acquire all outstanding shares of Dicerna for $38.25 per share.

The Dicerna merger investigation concerns whether the Board of Dicerna has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.